CN115698085A - 一种抗pd-l1和egfr的四价双特异性抗体 - Google Patents

一种抗pd-l1和egfr的四价双特异性抗体 Download PDF

Info

Publication number
CN115698085A
CN115698085A CN202180038398.6A CN202180038398A CN115698085A CN 115698085 A CN115698085 A CN 115698085A CN 202180038398 A CN202180038398 A CN 202180038398A CN 115698085 A CN115698085 A CN 115698085A
Authority
CN
China
Prior art keywords
cancer
pdl1
egfr
bispecific antibody
tetravalent bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038398.6A
Other languages
English (en)
Inventor
朱祯平
黄浩旻
赵杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Publication of CN115698085A publication Critical patent/CN115698085A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

本发明提供了一种抗PD‑Ll和EGFR的四价双特异性抗体。本发明的四价双特异性抗体不需要进行Fc修饰，不会产生错配问题，制备方法简便，具有与单抗相似甚至更优的生物学活性和理化性质。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN202180038398.6A 2020-06-02 2021-06-01 一种抗pd-l1和egfr的四价双特异性抗体 Pending CN115698085A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020104876208 2020-06-02
CN202010487620.8A CN113754774A (zh) 2020-06-02 2020-06-02 一种抗pd-l1和egfr的四价双特异性抗体
PCT/CN2021/097784 WO2021244553A1 (zh) 2020-06-02 2021-06-01 一种抗pd-l1和egfr的四价双特异性抗体

Publications (1)

Publication Number Publication Date
CN115698085A true CN115698085A (zh) 2023-02-03

Family

ID=78782284

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010487620.8A Pending CN113754774A (zh) 2020-06-02 2020-06-02 一种抗pd-l1和egfr的四价双特异性抗体
CN202180038398.6A Pending CN115698085A (zh) 2020-06-02 2021-06-01 一种抗pd-l1和egfr的四价双特异性抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010487620.8A Pending CN113754774A (zh) 2020-06-02 2020-06-02 一种抗pd-l1和egfr的四价双特异性抗体

Country Status (3)

Country Link
CN (2) CN113754774A (zh)
TW (1) TW202146446A (zh)
WO (1) WO2021244553A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993901A (zh) * 2020-04-29 2022-01-28 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105820251B (zh) * 2015-01-08 2019-10-15 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993901A (zh) * 2020-04-29 2022-01-28 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途

Also Published As

Publication number Publication date
TW202146446A (zh) 2021-12-16
WO2021244553A1 (zh) 2021-12-09
CN113754774A (zh) 2021-12-07

Similar Documents

Publication Publication Date Title
US20230340097A1 (en) Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
EP3954712A1 (en) Anti-pd-l1/vegf bifunctional antibody and use thereof
JP7165265B2 (ja) Ｈｅｒ２／ｐｄ１二重特異性抗体
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
EP4047018B1 (en) Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereof
CN116096897A (zh) 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途
WO2021244553A1 (zh) 一种抗pd-l1和egfr的四价双特异性抗体
US20230257465A1 (en) ANTI-PDL1 x EGFR BISPECIFIC ANTIBODY
WO2021244552A1 (zh) 抗pdl1×kdr的双特异性抗体
WO2023273958A1 (zh) 三特异性抗体、其制备方法和用途
US20220135686A1 (en) Antibody that binds to human pd-l1
CN116284427A (zh) 抗muc17/cd3双特异性抗体、其制备方法及用途
CN116802297A (zh) 抗PD-L1/TGF-β双功能抗体及其用途
CN117586413A (zh) 异多聚体蛋白质及其制备方法
CN116419930A (zh) 结合her2的多价双特异性抗体、其制备方法和用途
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination